RecruitingPHASE1, PHASE2NCT03658785

Immunotherapy for the Treatment of Advanced Solid Tumor

Studying Cerebrotendinous xanthomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tongji Hospital
Principal Investigator
Hui Wang, MD
Tongji Hospital
Intervention
TIL(biological)
Enrollment
40 target
Eligibility
18-70 years · All sexes
Timeline
20202025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03658785 on ClinicalTrials.gov

Other trials for Cerebrotendinous xanthomatosis

Additional recruiting or active studies for the same condition.

See all trials for Cerebrotendinous xanthomatosis

← Back to all trials